Antitumor Effects of Combining Docetaxel (Taxotere) with the Antivascular Action of Ultrasound Stimulated Microbubbles

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Goertz, David E ^a,b   Todorova, Margarita ^a,b   Mortazavi, Omid ^b   Agache, Vlad ^b   Chen, Branson ^b   Karshafian, Raffi ^c   Hynynen, Kullervo ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b Sunnybrook Health Sciences Centre   (Canada)

^c RYERSON UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; ULTRASOUND STIMULATED MICROBUBBLE; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CONTROL; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HUMAN CELL; LONGITUDINAL STUDY; MALE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PARTICLE SIZE; PROSTATE CANCER; SURVIVAL TIME; TISSUE PERFUSION; TREATMENT DURATION; TUMOR NECROSIS; ULTRASOUND THERAPY; ULTRASOUND TRANSDUCER;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; HUMANS; MALE; MICE; MICE, NUDE; MICROBUBBLES; PROSTATIC NEOPLASMS; TAXOIDS;

MUS;

EID: 84871402947     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052307     Document Type: Article

References (74)

1. Bohmer MR, Chlon CH, Raju BI, Chin CT, Shevchenko T, et al. (2010) Focused ultrasound and microbubbles for enhanced extravasation. J Control Release 148: 18-24.
2. Unger EC, Porter T, Culp W, Labell R, Matsunaga T, et al. (2004) Therapeutic applications of lipid-coated microbubbles. Adv Drug Deliv Rev 56: 1291-1314.
3. Deckers R, Moonen CT, (2010) Ultrasound triggered, image guided, local drug delivery. J Control Release 148: 25-33.
4. Tannock IF, Lee CM, Tunggal JK, Cowan DS, Egorin MJ, (2002) Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. Clin Cancer Res 8: 878-884.
5. Jain RK, (2001) Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev 46: 149-168.
6. Ting CY, Fan CH, Liu HL, Huang CY, Hsieh HY, et al. (2012) Concurrent blood-brain barrier opening and local drug delivery using drug-carrying microbubbles and focused ultrasound for brain glioma treatment. Biomaterials 33: 704-712.
7. Treat LH (2009) Impact of Focused Ultrasound-enhanced Drug Delivery on Survival in Rats with Glioma.
8. Treat LH, McDannold N, Vykhodtseva N, Zhang Y, Tam K, et al. (2007) Targeted delivery of doxorubicin to the rat brain at therapeutic levels using MRI-guided focused ultrasound. Int J Cancer 121: 901-907.
9. Heath CH, Sorace A, Knowles J, Rosenthal E, Hoyt K, (2012) Microbubble therapy enhances anti-tumor properties of cisplatin and cetuximab in vitro and in vivo. Otolaryngol Head Neck Surg 146: 938-945.
10. Lin CY, Tseng HC, Shiu HR, Wu MF, Chou CY, et al. (2012) Ultrasound sonication with microbubbles disrupts blood vessels and enhances tumor treatments of anticancer nanodrug. Int J Nanomedicine 7: 2143-2152.
11. Watanabe Y, Aoi A, Horie S, Tomita N, Mori S, et al. (2008) Low-intensity ultrasound and microbubbles enhance the antitumor effect of cisplatin. Cancer Sci 99: 2525-2531.
12. Zhao YZ, Lu CT, Zhou ZC, Jin Z, Zhang L, et al. (2011) Enhancing chemotherapeutic drug inhibition on tumor growth by ultrasound: an in vivo experiment. J Drug Target 19: 154-160.
13. Minchinton AI, Tannock IF, (2006) Drug penetration in solid tumours. Nat Rev Cancer 6: 583-592.
14. Miller DL, (2007) Overview of experimental studies of biological effects of medical ultrasound caused by gas body activation and inertial cavitation. Prog Biophys Mol Biol 93: 314-330.
15. Hwang JH, Brayman AA, Reidy MA, Matula TJ, Kimmey MB, et al. (2005) Vascular effects induced by combined 1-MHz ultrasound and microbubble contrast agent treatments in vivo. Ultrasound Med Biol 31: 553-564.
16. Hwang JH, Tu J, Brayman AA, Matula TJ, Crum LA, (2006) Correlation between inertial cavitation dose and endothelial cell damage in vivo. Ultrasound Med Biol 32: 1611-1619.
17. Tachibana K, Uchida T, Ogawa K, Yamashita N, Tamura K, (1999) Induction of cell-membrane porosity by ultrasound. Lancet 353: 1409.
18. Leighton T (1997) The Acoustic Bubble. London: Academic Press. 613 p.
19. Wood AK, Ansaloni S, Ziemer LS, Lee WM, Feldman MD, et al. (2005) The antivascular action of physiotherapy ultrasound on murine tumors. Ultrasound Med Biol 31: 1403-1410.
20. Wood AK, Bunte RM, Price HE, Deitz MS, Tsai JH, et al. (2008) The disruption of murine tumor neovasculature by low-intensity ultrasound-comparison between 1- and 3-MHz sonication frequencies. Acad Radiol 15: 1133-1141.
21. Burke CW, Klibanov AL, Sheehan JP, Price RJ, (2011) Inhibition of glioma growth by microbubble activation in a subcutaneous model using low duty cycle ultrasound without significant heating. J Neurosurg 114: 1654-1661.
22. Goertz DE, Karshafian R, Hynynen K (2009) Association of cavitation with ultrasound stimulated blood flow modulation in tumours. (2009) IEEE International Ultrasonics Symposium, Rome, Italy 89-93.
23. Goertz DE, Karshafian R, Hynynen K (2008) Antivascular Effects of Pulsed Low Intensity Ultrasound and Microbubbles in Mouse Tumors. (2008) IEEE Ultrasonics Symposium, Beijing, China 670-673.
24. Wood AK, Schultz SM, Lee WM, Bunte RM, Sehgal CM, (2010) Antivascular ultrasound therapy extends survival of mice with implanted melanomas. Ultrasound Med Biol 36: 853-857.
25. Tozer GM, Kanthou C, Baguley BC, (2005) Disrupting tumour blood vessels. Nat Rev Cancer 5: 423-435.
26. Siemann DW, Mercer E, Lepler S, Rojiani AM, (2002) Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer 99: 1-6.
27. Siemann DW, (2011) The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents. Cancer Treat Rev 37: 63-74.
28. Horsman MR, Siemann DW, (2006) Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res 66: 11520-11539.
29. Siemann DW, Shi W, (2008) Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503). Anticancer Res 28: 2027-2031.
30. Shaked Y, Ciarrocchi A, Franco M, Lee CR, Man S, et al. (2006) Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 313: 1785-1787.
31. Shaked Y, Kerbel RS, (2007) Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy. Cancer Res 67: 7055-7058.
32. Shaked Y, Nathan P, Daenen LGM, Kerbel RS (2010) Combining Antiangiogenic Drugs with Vascular Disrupting Agents Rationale and Mechanisms of Action. In: Meyer T, editor. Vascular Disruptive Agents for the Treatment of Cancer: New York, Springer, Inc. 117-134.
33. McKeage MJ, Baguley BC, (2010) Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer. Cancer 116: 1859-1871.
34. Taraboletti G, Bonezzi K, Giavazzi R (2010) Combination Therapy with Chemotherapy and VDAs In: Meyer T, editor. Vascular Disruptive Agents for the Treatment of Cancer. New York: Springer. 77-93.
35. Siemann DW, Shi W, (2004) Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors. Int J Radiat Oncol Biol Phys 60: 1233-1240.
36. McKeage MJ, Fong P, Jeffery M, Baguley BC, Kestell P, et al. (2006) 5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent. Clin Cancer Res 12: 1776-1784.
37. Siim BG, Lee AE, Shalal-Zwain S, Pruijn FB, McKeage MJ, et al. (2003) Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother Pharmacol 51: 43-52.
38. McKeage MJ, (2008) The potential of DMXAA (ASA404) in combination with docetaxel in advanced prostate cancer. Expert Opin Investig Drugs 17: 23-29.
39. Pili R, Rosenthal MA, Mainwaring PN, Van Hazel G, Srinivas S, et al. (2010) Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC. Clin Cancer Res 16: 2906-2914.
40. Skeel R, editor (2007) Handbook of Cancer Chemotherapy. 7th ed. Philadelphia: Lippincott Williams & Wilkins.
41. Helfield BL, Huo X, Williams R, Goertz DE, (2012) The Effect of Preactivation Vial Temperature on the Acoustic Properties of Definity(TM). Ultrasound Med Biol 38: 1298-1305.
42. Dromi S, Frenkel V, Luk A, Traughber B, Angstadt M, et al. (2007) Pulsed-high intensity focused ultrasound and low temperature-sensitive liposomes for enhanced targeted drug delivery and antitumor effect. Clin Cancer Res 13: 2722-2727.
43. Bissery MC, Vrignaud P, Lavelle F, (1995) Preclinical profile of docetaxel (taxotere): efficacy as a single agent and in combination. Semin Oncol 22: 3-16.
44. Krix M, Kiessling F, Vosseler S, Kiessling I, Le-Huu M, et al. (2003) Comparison of intermittent-bolus contrast imaging with conventional power Doppler sonography: quantification of tumour perfusion in small animals. Ultrasound Med Biol 29: 1093-1103.
45. Turnbull DH, Ramsay JA, Shivji GS, Bloomfield TS, From L, et al. (1996) Ultrasound backscatter microscope analysis of mouse melanoma progression. Ultrasound Med Biol 22: 845-853.
46. Fenton BM, Paoni SF, Lee J, Koch CJ, Lord EM, (1999) Quantification of tumour vasculature and hypoxia by immunohistochemical staining and HbO2 saturation measurements. Br J Cancer 79: 464-471.
47. Duan WR, Garner DS, Williams SD, Funckes-Shippy CL, Spath IS, et al. (2003) Comparison of immunohistochemistry for activated caspase-3 and cleaved cytokeratin 18 with the TUNEL method for quantification of apoptosis in histological sections of PC-3 subcutaneous xenografts. J Pathol 199: 221-228.
48. McDannold NJ, Vykhodtseva NI, Hynynen K, (2006) Microbubble contrast agent with focused ultrasound to create brain lesions at low power levels: MR imaging and histologic study in rabbits. Radiology 241: 95-106.
49. Chen H, Kreider W, Brayman AA, Bailey MR, Matula TJ, (2011) Blood vessel deformations on microsecond time scales by ultrasonic cavitation. Phys Rev Lett 106: 034301.
50. Karshafian R, Bevan PD, Williams R, Samac S, Burns PN, (2009) Sonoporation by ultrasound-activated microbubble contrast agents: effect of acoustic exposure parameters on cell membrane permeability and cell viability. Ultrasound Med Biol 35: 847-860.
51. Sorace AG, Warram JM, Umphrey H, Hoyt K, (2012) Microbubble-mediated ultrasonic techniques for improved chemotherapeutic delivery in cancer. J Drug Target 20: 43-54.
52. Lin CY, Huang YL, Li JR, Chang FH, Lin WL, (2010) Effects of focused ultrasound and microbubbles on the vascular permeability of nanoparticles delivered into mouse tumors. Ultrasound Med Biol 36: 1460-1469.
53. Lin CY, Liu TM, Chen CY, Huang YL, Huang WK, et al. (2010) Quantitative and qualitative investigation into the impact of focused ultrasound with microbubbles on the triggered release of nanoparticles from vasculature in mouse tumors. J Control Release 146: 291-298.
54. Bekeredjian R, Kroll RD, Fein E, Tinkov S, Coester C, et al. (2007) Ultrasound targeted microbubble destruction increases capillary permeability in hepatomas. Ultrasound Med Biol 33: 1592-1598.
55. Kim TJ, Ravoori M, Landen CN, Kamat AA, Han LY, et al. (2007) Antitumor and antivascular effects of AVE8062 in ovarian carcinoma. Cancer Res 67: 9337-9345.
56. Yeung SC, She M, Yang H, Pan J, Sun L, et al. (2007) Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model. J Clin Endocrinol Metab 92: 2902-2909.
57. Head M, Jameson MB, (2010) The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities. Expert Opin Investig Drugs 19: 295-304.
58. Ching LM, Cao Z, Kieda C, Zwain S, Jameson MB, et al. (2002) Induction of endothelial cell apoptosis by the antivascular agent 5,6-Dimethylxanthenone-4-acetic acid. Br J Cancer 86: 1937-1942.
59. Ching LM, Zwain S, Baguley BC, (2004) Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice. Br J Cancer 90: 906-910.
60. Heldin CH, Rubin K, Pietras K, Ostman A, (2004) High interstitial fluid pressure- an obstacle in cancer therapy. Nat Rev Cancer 4: 806-813.
61. Schwartz EL, (2009) Antivascular actions of microtubule-binding drugs. Clin Cancer Res 15: 2594-2601.
62. Chappell JC, Klibanov AL, Price RJ, (2005) Ultrasound-microbubble-induced neovascularization in mouse skeletal muscle. Ultrasound Med Biol 31: 1411-1422.
63. Song J, Qi M, Kaul S, Price RJ, (2002) Stimulation of arteriogenesis in skeletal muscle by microbubble destruction with ultrasound. Circulation 106: 1550-1555.
64. Hu X, Kheirolomoom A, Mahakian LM, Beegle JR, Kruse DE,et al. Insonation of targeted microbubbles produces regions of reduced blood flow within tumor vasculature. Invest Radiol 47: 398-405.
65. Czarnota GJ, Karshafian R, Burns PN, Wong S, Al Mahrouki A, et al. (2012) Tumor radiation response enhancement by acoustical stimulation of the vasculature. Proc Natl Acad Sci U S A 109: E2033-2041.
66. Hori K, Nishihara M, Shiraishi K, Yokoyama M, (2010) The combretastatin derivative (Cderiv), a vascular disrupting agent, enables polymeric nanomicelles to accumulate in microtumors. J Pharm Sci 99: 2914-2925.
67. ter Haar GR, (2001) High intensity focused ultrasound for the treatment of tumors. Echocardiography 18: 317-322.
68. Staruch R, Chopra R, Hynynen K, (2011) Localised drug release using MRI-controlled focused ultrasound hyperthermia. Int J Hyperthermia 27: 156-171.
69. Ranjan A, Jacobs GC, Woods DL, Negussie AH, Partanen A, et al. (2012) Image-guided drug delivery with magnetic resonance guided high intensity focused ultrasound and temperature sensitive liposomes in a rabbit Vx2 tumor model. J Controlled Release 158: 487-494.
70. Rapoport N, Gao Z, Kennedy A, (2007) Multifunctional nanoparticles for combining ultrasonic tumor imaging and targeted chemotherapy. J Natl Cancer Inst 99: 1095-1106.
71. Tartis MS, McCallan J, Lum AF, LaBell R, Stieger SM, et al. (2006) Therapeutic effects of paclitaxel-containing ultrasound contrast agents. Ultrasound Med Biol 32: 1771-1780.
72. Wu F, Chen WZ, Bai J, Zou JZ, Wang ZL, et al. (2002) Tumor vessel destruction resulting from high-intensity focused ultrasound in patients with solid malignancies. Ultrasound Med Biol 28: 535-542.
73. Hynynen K, Chung AH, Colucci V, Jolesz FA, (1996) Potential adverse effects of high-intensity focused ultrasound exposure on blood vessels in vivo. Ultrasound Med Biol 22: 193-201.
74. Quesson B, Merle M, Kohler MO, Mougenot C, Roujol S, et al. (2010) A method for MRI guidance of intercostal high intensity focused ultrasound ablation in the liver. Med Phys 37: 2533-2540.